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Home testing for chlamydia and gonorrhea increases screening rates, but the cost consequences of this intervention are unclear.
We examined the cost diﬀerences between home-based and clinic-based testing and the cost-eﬀectiveness of home testing based
on the DAISY study, a randomized controlled trial. Direct and indirect costs were estimated for home and clinic testing, and cost-
eﬀectiveness was calculated as cost per additional test performed. In the clinic testing group, direct costs were $49/test and indirect
costs (the costs of seeking or receiving care) were $62/test. Home testing cost was $25/test. We found that home testing was cost
saving when all testing for all patients was considered. However cost savings were not seen when only asymptomatic tests or when
patient subgroups were considered. A home testing program could be cost saving, depending on whether changes in clinic testing
frequency occur when home testing is available.
Copyright © 2007 Kenneth J. Smith et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Hometestingforchlamydiaandgonorrheahashighsensitiv-
ity (about 90%) andspeciﬁcity (>99%), and is well accepted
in adolescent and young adult populations [1–3]. Studies in
the US and in Denmark demonstrate that home testing sig-
niﬁcantly increases the likelihood that tests will occur [1, 2].
It is well established that oﬃce-based screening for chlamy-
dia is a cost-eﬀective intervention for sexually active young
women [3–5], as is screening for gonorrhea in women with
individual or population risk factors [6, 7], however screen-
ing in clinical settings is not performed as often as is recom-
mended [8, 9].
Home screening, while increasing test frequency, might
decreasescreeningcosts,byavoidingclinicalfacilityandclin-
ician fees [1]. The indirect costs of clinic-based screening,
such as time oﬀ work or school, childcare, transportation,
and other costs resulting from a clinic visit, could also be
averted. In this analysis, we use test frequency and cost data
from a randomized trial of home testing for chlamydia and
gonorrhea in high-risk young women to examine cost diﬀer-
ences between home-based and clinic-based testing and the
cost-eﬀectiveness of a home testing intervention.
2. MATERIALS AND METHODS
The data source for this analysis was the Detection Accept-
ability Intervention for STD’s in Young women (DAISY)
study, a randomized controlled trial. Trial recruitment and
results are detailed elsewhere [1]. Brieﬂy, 398 young women
aged 15–24 at high risk for STD were recruited from clin-
ics and surrounding communities, representing a group
where frequent testing is recommended. Recruitment oc-
curred between November 2000-April 2003. Women were
randomized to an intervention group, who received home
testing kits for chlamydia and gonorrhea by mail at 6,
12, and 18 months, or a control group, who received a
postcard at 6, 12, and 18 months inviting them to at-
tend one of the participating study clinics for a rou-
tine test for women’s health infections at no cost. Par-
ticipants were urged to maintain their usual health pat-
terns, including evaluation for genital symptoms or STD’s.
Women with positive home tests were notiﬁed, counseled
about partner notiﬁcation, and referred to a participating
clinic for treatment at no cost. Signiﬁcantly more screen-
ing tests were performed in the home screening interven-
tion group, and no diﬀerences in STD incidence rates were2 Infectious Diseases in Obstetrics and Gynecology
seen between intervention and control groups over the study
period.
Allparticipantscompletedaquestionnaireatenrollment,
whichincludedquestionsaboutout-of-pocketcostsforseek-
ing or receiving care at the clinic, time oﬀ work or school due
to clinic visits, and time donated by others to allow the par-
ticipant to attend clinic. These questions and the number of
testsperformedinclinicandathomeinthetrialarethefocus
of this analysis.
The direct and indirect costs of receiving screening tests
were calculated for women randomized to the intervention
(testing at home) and for those in the control group (clinic
testing). Direct costs of clinic-based testing were the costs for
clinician time and for the test kit (nucleic acid ampliﬁcation
for chlamydia and gonorrhea), along with required supplies.
The Panel on Cost-Eﬀectiveness in Health and Medicine rec-
ommends including the following as indirect costs of care:
payments made by the patient in the course of seeking or re-
ceiving care, and time required by the patient and others to
allow care to be received [10]. In this analysis, indirect costs
for the clinic visits included costs of parking or transporta-
tion and of babysitting or childcare. Indirect costs for time
m i s s e df r o ms c h o o lo rw o r kt or e c e i v ec a r ea n df o rt i m ed o -
nated by others (e.g., for rides or babysitting) to allow care
to occur were quantiﬁed based on patient responses, then
valued based on the average hourly wage in 2005 for non-
farm workers in the US [11] to avoid bias against interven-
tion in this young population [10]; the eﬀects of other time
costs were examined in sensitivity analyses. Direct costs for
homescreeningwerethecostofthetest,packagingcosts,and
postage to and from the patient, costing a total of 25. Testing
costalone(includingmaterialsandtechniciantime)ineither
setting was 21. These costs were then applied to clinic-based
and home-based tests as quantiﬁed in the DAISY study, and
costs compared between intervention and control groups.
Alternative values for all cost components, varied individu-
ally and collectively over plausible ranges, were examined in
one-way and multiway sensitivity analyses.
Direct costs per subject for the intervention group and
the control group were calculated as follows: Direct cost
(clinic test) ∗ clinic test frequency + Direct cost (Home test)
∗ home test frequency divided by the number of subjects in
each group. Indirect costs were calculated similarly.
Cost-eﬀectiveness calculations were performed to esti-
matethecostperadditionaltestperformedpersubject,using
the formula

Total cost per subject (intervention)
−Tests per subject (intervention)


Total cost per subject (control)
−Tests per subject (control)

.
(1)
The model assumes equal STD incidence and diagnosis
with home- and clinic-based testing, as seen in the DAISY
trial, and hence the advantage of home testing from a cost-
eﬀectiveness standpoint (if any) is that, compared to the
clinic testing group, more tests are performed overall due to
testing at home (at a relatively low cost) while fewer tests are
performed in clinic (at higher cost).
Table 1: Demographic and economic questionnaire data from the
DAISY study.
Frequency Percent
All subjects 388 100%
Average age (years) 18.9 —
14–18 years old 181 46.6%
19–25 years old 207 53.4%
Recruitment site
Clinic 198 51.0%
Neighborhood 190 49.0%
No insurance 86 22.2%
Paid for parking/transportation 136 35.1%
Paid 5 or more 49 12.6%
Paid a babysitter 25 6.4%
Other person donated time 143 36.9%
Donated ≥1 hours 115 29.6%
Took time oﬀ from work or school 136 35.1%
≥2 hours 86 22.2%
Clinic visit took ≥2 hours 99 25.5%
Travel time to clinic >30 minutes 86 22.2%
One-way and probabilistic sensitivity analyses were per-
formed. Cost and time parameters were varied individu-
ally to examine eﬀects on model results. In the probabilistic
sensitivity analysis, these parameters were varied simultane-
ously, along with testing frequencies from the DAISY study,
through their 95% conﬁdence intervals, with values for each
parameter randomly chosen from distributions 10,000 times
and cost-eﬀectiveness ratios calculated for each parameter
set chosen. Parameter distributions were selected based on
the characteristics of each parameter. Uniform distributions,
where all values in the range were equally likely to be cho-
sen, were used for time cost per hour, nonclinician direct
costs for clinic-based testing, and home-based testing costs.
Gammadistributions,basedonDAISYstudymeanandstan-
dard deviation (SD) data, were used for indirect monetary
costs, time required to receive care, and for clinician costs.
Normal distributions were used for test frequencies.
3. RESULTS AND DISCUSSION
Questionnaire results are summarized in Table 1. Responses
to these questions were similar regardless of randomization
group, therefore results are reported for 388 subjects (10 of
the original 398 subjects had no questionnaire data avail-
able). Slightly more than one-ﬁfth of subjects had no insur-
ance, took more than 2 hours oﬀ school or work to attend
clinic,ortraveledmorethat30minutestoattendclinic;more
than a third paid for parking/transportation or had another
person donate time so that care could be obtained.
Costs per test received are summarized in Table 2.D i -
rect costs for clinic-based testing, including clinician and test
costs, were estimated at 49 per test received. On average, sub-
jects paid 2.97 for parking/transportation and childcare, and
3.7 hours were spent by the subject and others to allow careKenneth J. Smith et al. 3
Table 2: Direct and indirect costs per screening test received and
ranges examined in sensitivity analyses.
Base case Range
Costs of clinic screening
Direct costs
Clinician cost 28 12–50
Test cost 21 10–32
Indirect costs
Monetary (mean [SD])∗ 2.97 [7.55] 0–25
Time (hours) (mean [SD])† 3.7 [2.7] 0.4–10.5
Time value (per hour) 16 7–25
Costs of home screening
Direct costs
Test cost, packaging, and postage 25 15–35
∗ Parking/transportation plus babysitter/childcare.
† Time oﬀ work or school, plus time donated by others so that care could
be received.
to be received per clinic visit. Combined direct and indirect
costs per clinic visit totaled 111.
Table 3 displays tests performed, testing costs, and cost-
eﬀectiveness results for all study subjects and for subgroups
based on recruitment site. More tests and more asymp-
tomatic tests were performed among the home screening
group (P<. 0001), with greater diﬀerences in testing rates
seen in women recruited from neighborhoods. Women re-
cruited from clinics had high testing rates and a smaller
diﬀerential between home and clinic-based testing. No dif-
ference in STD incidence was noted between intervention
groups (20.4 [home testing] versus 24.1 [clinic testing] per
100 woman-years, P = .28).
Consideringtotalcostsforallsubjectsandalltesting,and
assuming equal STD detection between groups, the home
testing intervention was cost saving, because fewer clinic-
based tests were performed and the resulting cost savings
were not completely oﬀset by the costs of increased home
testing (Table 3). Total testing costs per infection found were
estimated at 702 in the intervention group and 717 in the
control group. However, cost savings were not noted for the
neighborhood recruitment subgroup, where each additional
testobtainedbytheinterventiongroupcomparedtothecon-
trol group cost about 24.50, due to more frequent home-
based testing and no decrease in clinic testing with the in-
tervention. When only asymptomatic testing was considered
in all subjects, the intervention cost was 12.51 per additional
testperformed,sincethecostsofincreasedhometestingwere
notoﬀsetbytherelativitysmalldecreasesinclinic-basedtest-
ing in the intervention group.
In one-way sensitivity analyses, four parameter values
varied individually through their listed ranges (Table 2)
made the total cost per subject of all testing in the inter-
vention group greater than the total cost per subject in the
control group (Table 4). The model was most sensitive to
changes in home testing costs, with increases in this cost of
≥5 making the home testing intervention more expensive
than clinic testing; to have similar eﬀects, time spent seek-
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Figure 1: Two-way sensitivity analysis on changes in testing rates
resulting from a home testing intervention. The line represents
points where the overall costs of a home testing program or clinic-
based testing are equal when gonorrhea and chlamydia detection
rates are the same with either program. Points denoting changes in
home and clinic testing frequency occurring due to a home testing
program that fall in the area below the line (e.g., the “X”) indicate
that cost savings would occur with that program. Points above the
line (e.g., the open square) denote parameter values where cost sav-
ings would not occur.
ing/receiving care, the cost of that time, or clinic testing cost
would need to decrease by about a third. Most importantly,
if infection detection frequency is not equal between groups,
unlike the equal detection seen in the DAISY trial and as-
sumed in this analysis, between-group diﬀerences in infec-
tion costs and complication eﬀects would need to be explic-
itly accounted for in the analysis.
In the probabilistic sensitivity analysis, where all cost and
testing parameters were varied simultaneously, the interven-
tion was cost saving in 52% of model iterations when all test-
ing was considered. When considering only asymptomatic
testing, there was a 22% likelihood that the intervention
would be cost saving.
Figure 1 illustrates the relationship of changes in testing
rates to cost savings with a home testing program if infec-
tion detection rates are equal between groups. If per-patient
clinic testing rates decrease by more than 22.5% of the in-
crease seen in home testing rates due to program adoption,
a home testing program will be cost saving. For example, if a
home testing intervention increases home testing in a popu-
lationby1testperpatientperyearanddecreasesyearlyclinic
testing by 0.4 tests per patient (denoted by the “X” in Fig-
ure 1), then the intervention would be cost saving. However,
with the same increase in home testing, if the clinic testing
rate only decreases by 0.1 test per patient (denoted by the
open square), then a home testing program is not cost sav-
ing.
In this analysis of a program encouraging home test-
ing for chlamydia and gonorrhea in a high-risk group of
young women, we found that, when all costs and all tests
were considered, a home testing program was cost saving
in the DAISY study, a randomized, controlled trial, while,
at the same time, signiﬁcant increases in all tests and in
asymptomatictestswereseen.However,whethercostsavings4 Infectious Diseases in Obstetrics and Gynecology
Table 3: Number of tests completed, testing costs, and cost-eﬀectiveness of the home screening intervention.
Tests completed Cost per subject Cost per additional
Clinic Home Total Per subject Direct Indirect Total test completed
All tests
All subjects Clinic testing (n = 191) 511 2 513 2.7 132 166 298 —
Home testing (n = 197) 460 254 714 3.6 147 145 292 Cost saving
Clinic recruits Clinic testing (n = 99) 395 1 396 4.0 197 248 445 —
Home testing (n = 99) 337 119 456 4.6 198 212 409 Cost saving
Neighborhood recruits Clinic testing (n = 92) 116 1 117 1.3 62 78 141 —
Home testing (n = 98) 123 135 258 2.6 96 78 174 24.50
Asymptomatic tests
All subjects Clinic testing (n = 191) 274 0 274 1.4 71 89 160 —
Home testing (n = 197) 261 173 434 2.2 87 82 169 12.51
Clinic recruits Clinic testing (n = 99) 199 0 199 2.0 99 125 224 —
Home testing (n = 99) 183 77 260 2.6 110 115 225 2.16
Neighborhood recruits Clinic testing (n = 92) 75 0 75 0.8 40 51 91 —
Home testing (n = 98) 78 96 174 1.8 64 49 113 23.13
Table 4: One-way sensitivity analysis, all subjects and all testing.
Parametervalueswherethehometestinginterventionismorecostly
than clinic-based testing.
Parameter Baseline value Home testing
more costly
Time spent receiving care
Hours 3.7 <2.5
Cost per hour 16 <11
Testing costs
Home 25 >30
Clinic direct costs
(clinician & test costs) 49 <32
occurred with home testing depended on the patient group
and clinical situation studied, based on changes in clinic-
based testing resulting from the intervention when STD de-
tection is the same with either testing program. Cost savings
were seen in clinic-recruited subjects, a group that utilized
clinic services more frequently, due to decreases in clinic-
based testing resulting from the availability of home test-
ing. In subjects recruited from neighborhoods surround-
ing the clinics, home testing was not cost saving, because
of increased home testing without proportionate clinic test-
ing reductions or STD detection improvements. When only
asymptomatic tests were considered, home testing was again
notcostsaving.Finally,theindirectcostsofseekingorreceiv-
ing care, that is, monetary costs for childcare, parking, and
other expenses; time costs from missed work or school; and
time donated by others were considerable and could present
barriers to receiving recommended testing and care.
As suggested by this analysis and by the DAISY study it-
self, the decision to implement a home testing intervention
for chlamydia and gonorrhea is more complex than merely
seeking to maximize tests performed or to minimize costs.
Home testing programs have been well demonstrated to in-
crease testing volume [1–3], by decreasing some barriers to
STDtestingthroughtheuseofarelativelyexpensivetest.Un-
less direct costs incurred by individual clinics could be de-
creased as a result of a home testing intervention, in times
of budgetary limitations clinics would have no incentive or
means to implement such an intervention. Indirect cost sav-
ings (when the intervention is considered from the broader,
societal standpoint) and the public health beneﬁts of in-
creased testing suggest that ﬁnancial support for home test-
ing would need to come from higher levels for these soci-
etal beneﬁts to be obtained. For individual clinics with a high
proportionoffrequentlyutilizingpatients,ahometestingin-
tervention could decrease the visit frequency by this patient
group, increasing capacity for other needed services and pa-
tient groups. In diﬀerent populations where care-related in-
direct costs might be higher, for example, due to clinic inac-
cessibility or unavailability, home testing might prove more
useful from clinical and economic standpoints by increasing
testing rates through decreasing individual disincentives for
testing. Concerns about home testing decreasing necessary
clinic visits appear to be unfounded [1].
Costsavingswerenotseenwhenonlyasymptomatictests
areconsidered,implyingthathometestingforscreeningpur-
poses may not be economically favorable. However, the dis-
tinction of symptomatic and asymptomatic testing might be
somewhat artiﬁcial when a population is considered, since
the availability of home tests could have beneﬁts beyond
those of screening. For example, delays in seeking care when
symptomatic are common, and the availability of home test-
ing may allow infections to be diagnosed sooner, potentially
decreasing untreated illness burden and PID risk. No diﬀer-
ences in infection detection were seen between randomiza-
tion groups in the DAISY study, where an urban population
with relatively easy and frequent access to care was investi-
gated; populations with less access could beneﬁt more from
home screening. Finally, few screening interventions are cost
saving, with some cost per health beneﬁt gained absorbed by
society or payers based on the magnitude of screening costsKenneth J. Smith et al. 5
a n db e n e ﬁ t sg a i n e d[ 12]. For example, Hu et al. [4]f o u n d
that annual chlamydia screening cost 2350 per quality ad-
justed life year gained compared to no screening and thus
would be considered very cost-eﬀective compared to other
health care interventions. In our analysis, where equal infec-
tion rates are seen between intervention groups, the cost per
health beneﬁt gained depends on the beneﬁts of greater test-
ing frequency for infected women and their partners. Unfor-
tunately, these beneﬁts cannot be estimated based on present
data, a limitation of our analysis.
4. CONCLUSIONS
A home testing intervention for chlamydia and gonorrhea,
whileincreasing testing rates,hasthe potential to be costsav-
ing when the direct and indirect costs of avoided clinic visits
are considered. The cost equation depends in large part on
whether changes in clinic testing frequency and STD detec-
tion occur as a result. Home testing eﬀects on clinic testing
frequency in other populations and on individual and pop-
ulation health in localities with more limited health services
require further research.
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